Biotech Values

[lgonber]

ESPR drug reduction of hsCRP is a positive, taking into account what is known in regards to prevention and management of cardiovascular disease. “Patients treated with bempedoic acid also achieved a significantly greater reduction of 33 percent in high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease”